Compare Abbott Laboratories (ABT) vs Uranium Energy Corp (UEC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Uranium Energy Corp — how do they compare? Abbott Laboratories trades at $95.31 (market cap $166.94B), while Uranium Energy Corp trades at $9.86 (market cap $4.90B). The key difference: Abbott Laboratories is far larger — about 34.1× Uranium Energy Corp's market cap, and Abbott Laboratories pays a 2.63% dividend while Uranium Energy Corp pays none. Which is the better fit depends on your goals.
| ABT | UEC | |
|---|---|---|
Market Cap | $166.94B | $4.90B |
Sector | Health | Energy |
52-Week High | $136.62 | $20.14 |
52-Week Low | $82.57 | $5.92 |
Enterprise Value | $193.69B | $4.41B |
Dividend Yield | 2.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
UEC trades at $10.57, down 2.22% today, amid bearish technical signals and weak quarterly results. The stock shows negative profitability with a -513.24% net income margin and has missed earnings expectations in two of the last three quarters. However, analyst sentiment remains strongly positive with 87.5% buy ratings, supported by the company's strategic positioning in uranium production and substantial liquidity of $794 million with no debt.
The outlook is mixed: strong analyst support and nuclear sector tailwinds offer long-term potential, but near-term risks include persistent losses, high valuation multiples, and operational execution challenges. Investors should weigh the company's asset base and market position against its current financial performance and cost pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Uranium Energy Corp
Uranium Energy Corp is a leading American uranium mining and exploration company, currently holding the largest resource base and licensed production capacity in the United States. Utilizing low-cost, environmentally friendly In-Situ Recovery (ISR) mining, UEC is a central player in the domestic nuclear fuel supply chain, transitioning from a resource holder to an active producer and refiner to meet the accelerating demand for carbon-free energy.
Read more on UEC →
